EUCTR2006-001680-33-IT进行中（未招募）不适用
Phase IV, Double-blind, Multi-center, Randomized, Cross-over Study to Compare 0.10 mmol/kg of MultiHance R with 0.10 mmol/kg of Omniscan R in Magnetic Resonance Imaging MRI of the Brain - Crossover Comparison of MultiHance R and Omniscan R in Brain Tumors
BRACCO IMAGING0 个研究点目标入组 114 人开始时间: 2006年6月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Enroll subjects in this study if they meet the following inclusion criteria Are at least 18 years of age or older; Are able to give written informed consent and are willing to comply with the protocol requirements; Are scheduled to undergo MRI; Are willing to undergo two MRI procedures within 14 days; Have confirmed or are highly suspected to have brain tumor s , as determined by at least one of the following clinical/neurological symptomatology; diagnostic testing, such as CT or previous MRI examinations from 30 days to 24 hours prior to the first MRI exam; have had recent surgery within 6 months and are to be evaluated for recurrence
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclude subjects from this study if they do not fulfill the inclusion criteria, or if any of the following conditions are observed. Are pregnant or lactating females. Exclude the possibility of pregnancy by testing on site at the institution serum or urine 61538;HCG within 24 hours prior to the start of each investigational product administration; or by history i.e., tubal ligation or hysterectomy ; or post menopausal with a minimum of 1 year without menses. Have any known allergy to one or more of the ingredients in the investigational products, or have a history of hypersensitivity to any metals. Have congestive heart failure class IV according to the classification of the New York Heart Association . Have suffered a stroke within a year. Have received or are scheduled to receive any other contrast medium in the 24 hours preceding through the 24 hours following Exam 1, and in the 24 hours preceding through the 24 hours following Exam 2. Have received an investigational compound and/or medical device within 30 days before admission into the present study, and/or are scheduled to 24 hours post-administration of the second investigational product. Have been previously entered into this study. Have received or are scheduled for one of the following Surgery within three weeks prior to the first examination or between the two examinations; Initiation of steroid therapy between the two examinations; Radiosurgery between the two examinations Have any contraindications to MRI such as a pace-maker, magnetic material i.e., surgical clips or any other conditions that would preclude proximity to a strong magnetic field. Are suffering from severe claustrophobia. Have any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.
研究者
相似试验
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kggenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-HUF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-NLF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
1 期
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSEUCTR2005-005507-41-GBF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
1 期
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infectionMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-FRF. Hoffmann-La Roche Ltd1,140
进行中（未招募）
不适用
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg - PROGRESSgenotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kgMedDRA version: 8.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2005-005507-41-DEF. Hoffmann-La Roche Ltd1,140